Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Clinical Effects
Potential for increased risk of bleeding
Management
Dosing depends on indication and renal function. For DVT and PE, avoid co-administration if CrCL < 50 mL / min. For stroke and embolism prevention in persons with atrial fibrillation, do not coadminister in severe renal insufficiency (CrCL< 30mL / min) and consider dose reduction to 75 mg twice daily if CrCL between 30 - 50mL / min
Import ID
236
